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BRIEF COMMUNICATIONS: RESEARCHHeparin-induced thrombocytopenia (HIT) is a prothrom-
botic condition characterized by a platelet decrease of
50% or thrombosis with a temporal relationship of 1 to 2
weeks after the initiation of heparin. These surrogate
markers are useful for the clinical assessment1 but are hardly
applicable in multimorbid patients with clinical conditions
that mimic HIT. Platelet activation assays (heparin-induced
platelet activation [HIPA] and serotonin release assay) and
platelet factor 4 (PF4)/polyanion enzyme-linked immuno-
sorbent assay (ELISA) confirm HIT.2 HIPA and serotonin
release assay are highly specific, but they are laborious
and require selected donor platelets and extended
experience. High titer immunoglobulin (Ig)G antibodies
correlate with clinical HIT,3 but ELISA is also time-con-
suming. The alternative heparin/PF4-antigen particle gel
immunoassay (PaGIA) is easy, provides results within 1
hour, and detects mainly IgG but also IgA/M antibodies.
We evaluated the specificity and sensitivity of PaGIA in re-
lation to HIPA and ELISA in 285 patients with an undeter-
mined likelihood for HIT with the intention to validate it as
a rapid assay to exclude HIT.
PATIENTS AND METHODS
Samples from 285 consecutive patients (median 71 years, range 1–97
years, 45% cardiovascular surgery; female/male 56/73, and 55% medical,
female/male 78/78) and 89 healthy controls (median 42 years, range 26–
64 years; female/male 49/40) were tested prospectively. The PaGIA (ID-
PaGIA H/PF4, DiaMed, Cressier s/Morat, Switzerland) was performed as
described4 and evaluated by 2 independent technicians. Briefly, heparin/
PF4-coated red particles become crosslinked in the presence of heparin
antibodies and remain on top of a gel chamber after centrifugation. In
the absence of antibodies, all particles sediment to the bottom of the
gel chamber. A combined anti-human IgG/A/M and anti-human IgG
only conjugate were used for the PF4-ELISA (PF4-ENHANCED; GTI,
Waukesha, Wis) following the manufacturer’s instructions. HIPA was
performed as published.5 Analyses include chi-square, Mann-Whitney,
receiver operating characteristic (ROC) curves (HIPA vs ELISA to deter-
From the University Clinic of Blood Group Serology and Transfusion Medicine,a
Department of Hematology and Stem Cell Transplantation, University Clinic of
Internal Medicine,b Office for Biostatistics, Center for Medical Research,c Medical
University of Graz, Austria; Institute for Transfusion Medicine Dessau, Red Cross
Blood Transfusion Service NSTOB,d Dessau, Germany; and Clinical Department of
Blood Group Serology,e Medical University of Vienna, Austria.
Received for publication Nov 27, 2007; accepted for publication March 18, 2008.
Address for reprints: Simon Panzer, MD, Clinical Department of Blood Group Serology,
Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria
(E-mail: simon.panzer@meduniwien.ac.at).
J Thorac Cardiovasc Surg 2009;137:781-3
0022-5223/$36.00
Copyright  2009 by The American Association for Thoracic Surgery
doi:10.1016/j.jtcvs.2008.03.044The Journal of Thoracic and Cmine their cutoff values), Bayes’ theorem, and logistic regression. Data
are presented as median and range.
RESULTS
HIPA was positive in 12% of patients. On the basis of
ROC curves (ELISA vs HIPA), optical density (OD) cutoff
values for the IgG/A/M-ELISA and IgG-ELISA were
0.761 and 0.564, respectively. In controls, the OD value
of the IgG-ELISA was 0.066 (0.028–0.500) and lower
than from patients’ samples, which were negative by Pa-
GIA and IgG/A/M-ELISA (n ¼ 158; 0.074; 0.009–
0.339; P ¼ .017). Of note, 2 male controls who had never
received heparin had IgG-ELISA OD values of 0.425 and
0.500. The latter serum was also positive by PaGIA, but
both were HIPA negative. The OD values of the other
87 controls were less than 0.180.
PaGIA was positive in 70 patients (25%), and the relation
to HIPA and ELISAs is shown in Table 1. In both patient
groups, both ELISA ODs were higher if PaGIA and IgG/
A/M-ELISA were positive compared with negative PaGIA
but positive IgG/A/M-ELISA (P< .001). The frequency
of PaGIA-positive samples was similar among surgical
and medical patients in all OD ranges (Figure 1). Three Pa-
GIA-negative samples were HIPA positive, and one was
IgG-ELISA positive.
On the basis of ROC curves (ELISA vs HIPA), IgG/A/
M-ELISA (OD cutoff 0.761) and IgG-ELISA (OD cutoff
0.564) had sensitivities of 81% and 86%, and specific-
ities of 75% and 81%, respectively (positive and negative
predictive values were 31% and 97% and 39% and 98%,
respectively, for IgG/A/M-ELISA and IgG-ELISA). Spec-
ificity, sensitivity, positive predictive value, and negative
predictive value of PaGIA based on HIPA and ELISA
are shown in Table 2. Logistic regression analysis showed
that PaGIA, IgG/A/M-ELISA, and IgG-ELISA were sig-
nificant predictors for the results of HIPA (P < .001)
and that the IgG-ELISA had the highest explained vari-
ance (41.2%). There were no differences between male
and female patients concerning specificity and sensitivity
of any test.
DISCUSSION
The high mortality associated with HIT led to an increas-
ing demand for its laboratory exclusion in patients with
various clinical conditions that mimic HIT, particularly be-
cause multimorbid patients are more likely to form PF4 an-
tibodies.2 The clinical score is highly reliable to excludeardiovascular Surgery c Volume 137, Number 3 781
Brief CommunicationsTABLE 1. Optical density values of the immunoglobulin-G/A/M enzyme-linked immunosorbent assay and immunoglobulin-G enzyme-linked
immunosorbent assay in surgical and medical patients in relation to the results of the particle gel immunoassay
OD IgG/A/M ELISA OD IgG ELISA
PaGIA IgG/A/M ELISA Median (range) Median (range)
Surgical patients n ¼ 129 Positive 28 Positive 28 1.813 (0.406–3.000) 1.007 (0.112–3.000)
Negative 0 – –
Negative 101 Positive 15 0.481 (0.407–1.604) 0.270 (0.046–1.481)
Negative 86 0.154 (0.060–0.395) 0.068 (0.021–0.339)
Medical patients n ¼ 156 Positive 42 Positive 36 1.806 (0.456–3.000) 1.480 (0.061–3.000)
Negative 6 0.157 (0.114–0.339) 0.117 (0.044–0.233)
Negative 114 Positive 42 0.520 (0.402–1.736) 0.242 (0.048–2.028)
Negative 72 0.181 (0.050–0.397) 0.076 (0.020–0.313)
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FIGURE 1. Distribution of surgical and medical patients with positive and negative PaGIA results in 3 OD intervals of the IgG-ELISA. The frequency
of PaGIA-positive and negative samples was similar among surgical and medical patients in all OD ranges (<0.564, P ¼ .1; 0.564–1.000, P ¼ .3;
>1.000, P ¼ 1.0). PaGIA, Particle gel immunoassay.TABLE 2. Relation of the particle gel immunoassay to heparin-induced platelet activation test and to immunoglobulin-G/A/M and immunoglobulin-G
enzyme-linked immunosorbent assay
PaGIA vs HIPA PaGIA vs IgG/A/M-ELISA PaGIA vs IgG-ELISA
Surgical Medical Surgical Medical Surgical Medical
Sensitivity% 71 79 92 73 86 73
Specificity% 68 75 94 89 92 85
PPV% 21 32 79 69 67 57
NPV% 95 96 98 90 97 92
PaGIA, Particle gel immunoassay; HIPA, heparin-induced platelet activation test; Ig, immunoglobulin; ELISA, enzyme-linked immunosorbent assay; PPV, positive predictive
value; NPV, negative predictive value.HIT when clinical features are unambiguous, but a rapid
assay is desirable for patients with undeterminable proba-
bility for HIT. Two commercialized assays provide results
within 1 hour: the PaGIA and PIFA (Akers Biosciences,
Thorofare, NJ). Reports to the Platelet Immunology Scien-
tific Subcommittee (Geneva 2007) suggest a low specificity
for the PIFA.
According to our results, the PaGIA can serve as a rapid
test to exclude HIT because a negative PaGIA is rarely asso-
ciated with high titer IgG PF4 antibodies or a positive HIPA.782 The Journal of Thoracic and Cardiovascular SuNotably, PaGIA is negative in rare non-PF4 antibody-medi-
ated HIT.5 Alternative anticoagulation should be considered
until results from functional testing are available if the Pa-
GIA is positive and in patients with a high probability for
HIT and a negative PaGIA.
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Autologous pericardium has been widely used to repair des-
tructed annuli in infective endocarditis complicated by annu-
lar abscess.1,2 In the present study we investigated the in
vitro property of autologous pericardium for a sustained-
release carrier of vancomycin.
CLINICAL SUMMARY
Between January and May 2002, autologous pericardium
with pericardial fat was harvested from the patients (n ¼ 6)
who underwent cardiac operations in our institute. After har-
vesting, the pericardium was cut into 7 pieces (1 cm3 1 cm
each). Then 0.2 mL of vancomycin solution (15mg/mL) was
dropped onto each pericardium and incubated for 1 hour at
room temperature so that the vancomycin solution was com-
pletely absorbed into the pericardium. The 7 pericardial
patches with vancomycin were soaked in 7 test tubes con-
taining 5 mL of saline, respectively. The test tubes were
placed in the shaker and kept at 37C. At 6 hours, 12 hours,
and 1, 3, 5, 7, and 10 days after the incubation, the pericar-
dium and the saline samples were collected and frozen from
1 of the 7 test tubes, and the saline in the residual test tubes
were replaced with 5 mL of fresh saline (ie, the pericardia
were left uncollected), respectively. We replaced the saline
in the residual test tubes at each time point to maintain the
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diffusion gradient between the pericardium and the saline.
To prevent the degradation of the samples, we froze them
until the concentrations of vancomycin were measured.
The vancomycin concentrations of the pericardium and the
saline samples were measured as previously described.3,4
We obtained written informed consent from each patient af-
ter a full explanation of this study. The protocol of this study
complied with the principles set forth in the Helsinki Decla-
ration.
All values are expressed as means  standard deviations.
Figure 1 shows that the percentage reaming of vancomycin
in the pericardium at each time point was 67.8%  17.8%,
53.8% 12.3%, 37.8% 9.8%, 25.1% 10.1%, 12.6%
 3.3%, 7.1%  3.1%, and 4.3%  1.7% for 6 hours,
12 hours, and 1, 3, 5, 7, and 10 days after the incubation,
respectively. Figure 2 shows that the concentrations of
vancomycin in the saline samples were 789  143 mg/mL,
376  56 mg/mL, 144  23 mg/mL, 56  14 mg/mL, 38 
5.2 mg/mL, 27  3.8 mg/mL, and 15  2.7 mg/mL for
6 hours, 12 hours, and 1, 3, 5, 7, and 10 days after the incu-
bation, which were all greater than the minimum inhibitory
concentration of vancomycin (2.0 mg/mL) against methicil-
lin-resistant Staphylococcus aureus (MRSA). These results
indicate that the pericardium can slowly release vancomycin
and maintain the minimum inhibitory concentration of
MRSA around the pericardium for more than 10 days.
DISCUSSION
In the present study we found that the autologous pericar-
dium with fat might have a potential for a sustained-release
carrier of vancomycin. Although this is an in vitro study and
the mechanism of the sustained release was unclear, the
property might help prevent prosthetic valve endocarditis
by MRSA after reconstruction of the infected annulus.
Antibiotics are usually administrated systematically to
prevent all forms of infection; however, this might be
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